Floatz logo

rc48-adc

Anal Carcinoma

SOLTI Breast Cancer Research Groupantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Anal Carcinoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 2B
Pyrotinib
SOLTI Breast Cancer Research Group
Phase 2CCC
Tislelizumab
SOLTI Breast Cancer Research Group
Phase 2CCC
Prasterone
Ohio State University Comprehensive Cancer Center
Phase 2CCC
OPA-INTERACTING PROTEIN 4
Mannkind Corporation
Phase 1CC
Spartalizumab
SOLTI Breast Cancer Research Group
Phase 2CC
Incb099318
Incyte Corporation
Phase 1CC
Hryz-T101 Tcr-T Cell
HRYZ Biotech Co.
Phase 1CC

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →